InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Shares Plans to Develop Scalable Psychedelic Facilitation Training Program
July 12, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is developing a streamlined, scalable version of its EMBARK Training Program, known as EMBARK for Clinical Trials, or EMBARK CT. The new offering is being developed as a scalable model of Embark, Cybin’s proprietary […]
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reports on Special Meeting
July 6, 2023
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is reporting on the results of its recent special meeting of shareholders. The meeting was held on July 4, 2023. According to […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Names New COO, Announces Participation in Upcoming London Symposium
June 30, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has appointed Aaron Bartlone as its chief operating officer; Bartlone has been the COO for Cybin’s U.S. subsidiary since March 2021. Bartlone has gathered impressive experience in his three-decade career, specifically in driving […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases FY 2023 Financial Report, Business Highlights
June 28, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on its audited financial results for the fiscal year ended March 31, 2023. Highlights of the report include total cash of C$16.6 million with net loss of C$13.7 million for the […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Names Seasoned Veteran as Strategic Advisor
June 27, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has appointed Sanford R. Climan as a strategic advisor. The CEO and founder of Entertainment Media Ventures Inc., Climan is an active venture investor who has also served as a board member and […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures US Patent for SPU-21 Treatment for Autoimmune Disease
June 21, 2023
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent 16/825,371 titled “Peptide-Targeted Liposomal Delivery for Treatment, Diagnosis and Imaging of Diseases and Disorders.” According to the announcement, the new patent claims cover the […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Participate at Psychedelic Science 2023 Conference
June 21, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company has announced that its Chief Executive Officer Doug Drysdale and SVP of Clinical Operations Allison House-Gecewicz will be speaking at the Psychedelic Science 2023 Conference hosted by the […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Participate at Upcoming H.C. Wainwright Neuropsychiatry Conference
June 15, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that its Chief Executive Officer Doug Drysdale will participate in a fireside chat at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference taking place on June […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Report on Status of Capital, Product Development
June 8, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on its capital and upcoming clinical milestones. As part of the report, the company noted it has C$70M in potential funding raised through a combination of a common share purchase agreement […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Changes in Scientific Management Team
June 5, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is making changes in its scientific management team. The company announced that Michael Palfreyman, PhD, and Brett Greene, both of whom joined Cybin as part of the acquisition of Adelia Therapeutics, will be […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at Jefferies Healthcare Conference
June 1, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options. The company today announced that its Chief Executive Officer Doug Drysdale will present at the Jefferies Healthcare Conference taking place in New York City from June 7-9, 2023. Drysdale’s presentation will […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Common Stock Purchase Agreement Totaling $30M
May 31, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has inked a common share purchase agreement with an institutional investor: Lincoln Park Capital Fund, LLC (“LPC”). According to the announcement, the agreement strengthens Cybin’s position to deliver on clinical milestones. The agreement […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Initiates Dosing of First Participants in Phase 1 Clinical Trial
May 24, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that the first participants have been dosed with CYB004 in its ongoing three-part phase 1 clinical trial evaluating intravenous N,N-dimethyltryptamine (“IV DMT”) and CYB004 in healthy […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Submits IND as Important Step in Advancing IBS Clinical Program
May 24, 2023
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs. The company today announced that it has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for its upcoming phase 2a […]
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Results of Annual General Shareholders Meeting
May 11, 2023
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is reporting on the results of shareholder voting at its annual general and special meeting (“AGSM”). The meeting was held May 5, […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Doses Last Subject in Phase 1, Part B CYB004-E Trial
May 9, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has completed dosing in part b of its three-part CYB004-E phase 1 trial. The study is designed to evaluate intravenous N,N-dimethyltryptamine (“IV DMT”) in healthy volunteers. The company also announced that it now […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Participate at Upcoming Milken Institute Global Conference
April 28, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, and its CEO Doug Drysdale will be spotlighted during the 26th annual Milken Institute Global Conference. The conference, slated for May 2, 2023, will be held in Beverly Hills California. Drysdale will be […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Closes on AUD $2.4M Oversubscribed Private Placement
April 27, 2023
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has closed on a private placement of secured convertible debentures. According to the company, the private placement resulted in gross proceeds of AUD$2.4 million, which represents an oversubscription of […]
InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Positive Preclinical Results on MYCO-006 Series
April 24, 2023
Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD. The company has announced promising pharmacokinetics and pharmacodynamics (“PKPD”) results from the MYCO-006 family in mouse models. According to the update, […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Private Placement for Minimum of AUD$2,000,000
April 13, 2023
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has announced a private placement. According to the announcement, the placement is for AUD$2.0 million and will include the ability to accept oversubscriptions of AUD$1.0m, of secured convertible […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Launches EMBARK OA, a Cost-Free Facilitator Training Program for Psychedelic Therapy
April 12, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, today announced the launch of EMBARK Open Access. “EMBARK OA” is the first and only free massive open online course that offers psychedelic facilitation training for health care professionals and people […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Marks Significant Step in Advancing Potential Groundbreaking Treatment for IBS
April 4, 2023
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs. The company today announced completion of the training of psychotherapists for its planned phase 2a clinical trial investigating the effects of psilocybin-assisted psychotherapy in the treatment of […]
InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Inks LOI for Acquisition of Ketamine Wellness Centers
April 4, 2023
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has signed a letter of intent with Peter/PetraMD, the largest online provider of hormone therapy in the United States for the acquisition of Ketamine Wellness Centers. According to the announcement, the acquisition provides an incredible on-ramp […]
Silo Pharma Inc. (NASDAQ: SILO) Provides Update on Innovative Study Looking into the Feasibility of Using Ketamine Formulations as an Alternative Treatment for Fibromyalgia
March 28, 2023
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced that it had achieved a positive outcome for its toxicology study of SP-26, its novel time-released, dosage-controlled formulation of ketamine. The results come after Silo Pharma had previously revealed that it was working on the preparation […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Positioned as Frontrunner in Psychedelic Drugs Market
March 24, 2023
Silo Pharma (NASDAQ: SILO) is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. “Silo Pharma has distinguished itself amongst peers for its ground-breaking research into conditions such as post-traumatic stress disorder (‘PTSD’), fibromyalgia, Alzheimer’s disease, and other rare neurological disorders. The company has recently entered into a number of studies designed […]
Silo Pharma Inc. (NASDAQ: SILO) Set to Benefit as Study Supports the Efficacy of Psychedelics in Treating ‘Drug-Resistant’ Depression
March 13, 2023
In a study carried out between 2013 to 2016, researchers found that 8.1% of American adults aged 20 and over suffered from depression during any given 2-week period, with women nearly twice as likely than men to have had acute depression (https://ibn.fm/ygq4x). Whilst depression has long been treated with a combination of self-help, talking therapies […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate at Oppenheimer 33rd Annual Health Care Conference
March 8, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced that its Chief Executive Officer Doug Drysdale will participate at the Oppenheimer 33rd Annual Health Care Conference taking place on March 13-15, 2023. Drysdale’s fireside chat will be webcast live on Tuesday, March 14, at 12:40 p.m. ET. […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Joins Chopra Foundation Founder, Other Experts in Psychedelics Discussions
March 3, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Doug Drysdale and Chopra Foundation founder Deepak Chopra will be participating together on a panel at the upcoming South by Southwest(R) (SXSW) Conference; the title of the panel is “Open Minds: Innovations in Consciousness, Psychedelics & Mental Health.” The SXSW event is slated for March 10–19, 2023, and will […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Progress Updates on Two Clinical Development Programs
February 28, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is reporting on its two lead clinical development programs: CYB003, a proprietary deuterated psilocybin analog for the potential treatment of major depressive disorder (“MDD”), and CYB004, a proprietary deuterated N,N-dimethyltryptamine molecule being developed for the potential treatment of generalized anxiety disorder […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Plan to Streamline Efforts, Maximize Efficiency, Focus on Clinical Trials
February 23, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a strategic plan designed to streamline efforts, maximize operating efficiency and focus on critical clinical trials, including near-term, mid-term and long-term milestones. A part of that plan was the release of an estimated 15% of Cybin’s workforce, including those […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q3 Financial Report, Corporate Highlights
February 14, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is reporting on its third quarter performance as well as recent business highlights; the report is for the period ended Dec. 31, 2022. In the report, the company noted that it had received approval from an independent ethics committee in the […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partnering to Transform Health Care, Improve Patient Outcomes
February 7, 2023
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”) examining the effect of psilocybin on inflammation. “Silo’s sponsored clinical trial with the Clinical & Translational Science Institute at UCSF aims to validate the use of psilocybin as a […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Approval for First-in-Human Dosing of Proprietary DMT Molecule
February 1, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received key approval to initiate human dosing of CYB004, its proprietary deuterated N,N-dimethyltryptamine (“DMT”) molecule, through a protocol amendment to its ongoing CYB004-E phase 1 trial. The approval came from an independent ethics committee in the Netherlands. The first-ever trial […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day
January 26, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has scheduled a virtual R&D Day for Feb. 28, 2023; the event is scheduled from 10 to 11:30 a.m. ET. The Cybin leadership team is slated to host the event, which will include an update on the company’s development pipeline of […]
Silo Pharma Inc. (NASDAQ: SILO) Provides Update on UCSF Psylocibin Clinical
January 26, 2023
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company that fuses traditional medicine with psychedelics, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”) examining the effect of psilocybin on inflammation. Research into psychedelics like psilocybin has recently experienced a renaissance, specifically for treating depression, addiction, […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Promising Results from Kernel Flow(R) Feasibility Study
January 18, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced key highlights from the completed feasibility study conducted by its partner HI, LLC dba Kernel (“Kernel”). The study was designed to evaluate Kernel’s Flow(R) wearable technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. “The results from […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Selects Generalized Anxiety Disorder as Target Indication for CYB004
January 12, 2023
Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(R). The company today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive disorder (“MDD”) as the target indication for CYB004 — its proprietary deuterated N, N-dimethyltryptamine (“DMT”) molecule. “Based on preclinical data, CYB004 has […]
Silo Pharma Inc. (NASDAQ: SILO) Provides Positive Update on Ongoing Study into the Use of Joint Homing Peptides as an Alternative Treatment for Rheumatoid Arthritis
January 12, 2023
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently revealed the positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents. The results come after the biopharmaceutical company initiated a pilot study on its novel joint homing […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances Clinical Study Examining Psilocybin’s Effect on Inflammation
January 10, 2023
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today provided a progress update on its sponsored research study with the University of California, San Francisco (“UCSF”). The study, which examines psilocybin’s effect on inflammatory activity in humans, evaluates three populations of patients suffering from Parkinson’s disease, […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Status Update on Clinical Development Programs
January 9, 2023
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is discussing upcoming priorities and near-term milestones regarding the status of its two clinical programs aimed at addressing multiple mental health conditions: CYB003 and CYB004. Designed for the treatment of Major Depressive Disorder (“MDD”), CYB003 is currently in a phase 1/2a […]